Tag Archives: PASI

October, 2018

19 October
New Three-Year Tremfya Data Demonstrates Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

LAS VEGAS, Oct. 19, 2018 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new long-term data from the open-label period of the VOYAGE 1 clinical trial demonstrating that stably maintained rates of skin clearance with TREMFYA® treatment achieved from week 52 (1 year) were maintained through week 156 (3 years) among …
Share

27 October
AbbVie’s Risankizumab Beats Humira and Stelara in Late-Stage Psoriasis Studies

NORTH CHICAGO, Ill., Oct. 26, 2017 /PRNewswire/ — AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced positive top-line results from three pivotal Phase 3 clinical trials evaluating risankizumab, an investigational interleukin-23 (IL-23) inhibitor, compared to ustekinumab and adalimumab for the treatment of patients with moderate to severe chronic plaque …
Share

29 September
Prothena Discontinues Development of PRX003 in Psoriasis Following Negative Trial Results

DUBLIN, Ireland, Sept. 28, 2017 (GLOBE NEWSWIRE) — Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced clinical results of a Phase 1b multiple ascending dose (MAD) study of PRX003 in patients with psoriasis. PRX003 is a …
Share
13 September
Novartis’ Cosentyx Sets New Benchmark in Psoriasis with Robust 5-Year Sustained Phase 3 Efficacy and Safety Data

Basel, September 13, 2017 – Novartis announced today, first of its kind Phase III data showing Cosentyx® (secukinumab) delivered high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis at 5 years[1]. These data were presented for the first time at the 26th European Academy of Dermatology and Venereology (EADV) Congress in Geneva, …
Share

9 October
Boehringer Ingelheim’s Psoriasis Drug Demonstrates Positive Mid-Stage Results

Ingelheim, Germany, October 8, 2015 – New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim’s investigational biologic compound BI 655066*, over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in …
Share